Wednesday, July 8, 2026

Patent intelligence · US

US 6238605

Low-fibrillation moulded bodies

expired A61KA61K8/02
Status expired
Linked drugs 1
Pipeline programs 5
Years to expiry 0
Applicant portfolio 20
Patent details — US 6238605

Quick answer

US 6238605 (Low-fibrillation moulded bodies) is held by LENZING AKTIENGESELLSCHAFT. Status: expired. Granted May 29, 2001. Expires May 24, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
45
CPC classes
A61K, A61K8/02

More from LENZING AKTIENGESELLSCHAFT

Related pharmaceutical patents in our USPTO index.

  1. US 12414942

    Compositions, methods, and systems for treating presbyopia

    LENZ THERAPEUTICS OPERATIONS, INC. · Expires Sep 11, 2045

    granted
  2. US 12180206

    Aceclidine derivatives, compositions thereof and methods of use thereof

    LENZ THERAPEUTICS OPERATIONS, INC. · Expires Dec 26, 2044

    granted
  3. US 12128036

    Compositions and methods for storage stable ophthalmic drugs

    LENZ THERAPEUTICS OPERATIONS, INC. · Expires Oct 24, 2044

    granted
  4. US 11648247

    Compositions and methods for the treatment of presbyopia

    Lenz Therapeutics, Inc. · Expires May 11, 2043

    granted
  5. US 11344538

    Methods for the treatment of myopia

    Lenz Therapeutics, Inc. · Expires May 26, 2042

    granted
  6. US 11273150

    Compositions and methods for the treatment of presbyopia

    Lenz Therapeutics, Inc. · Expires Mar 10, 2042

    granted
  7. US 11214569

    Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof

    Lenz Therapeutics, Inc. · Expires Dec 30, 2041

    granted
  8. US 11179328

    Compositions and methods for the treatment of presbyopia

    Lenz Therapeutics, Inc. · Expires Nov 18, 2041

    granted

Frequently asked questions

What is US patent 6238605?

US 6238605 (Low-fibrillation moulded bodies) is held by LENZING AKTIENGESELLSCHAFT. Status: expired. Granted May 29, 2001. Expires May 24, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6238605?

LENZING AKTIENGESELLSCHAFT is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.

When does US 6238605 expire?

Our index shows an expiration date of May 24, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.